Oncology (all articles)
Validation of the geriatric vulnerability score in older patients with ovarian cancer.
27 Sep, 2022 | 13:00h | UTC
20-year follow-up of a RCT | Adjuvant Goserelin and Tamoxifen in premenopausal patients with breast cancer.
26 Sep, 2022 | 12:00h | UTCNews Release: Hormonal breast cancer treatment reduces long-term risk of recurrence – Karolinska Institutet
Commentary on Twitter
20-yr FU of the STOCKHOLM trial in pts with premenopausal #breastcancer reveals that those with genomic low-risk benefited most from tamoxifen & those with genomic high-risk from goserelin, with no benefit from combined goserelin-tamoxifen in either group: https://t.co/UDKo5huaFA
— NatureRevClinOncol (@NatRevClinOncol) August 4, 2022
M-A | Margin status and survival outcomes after breast cancer conservation surgery.
23 Sep, 2022 | 13:09h | UTCCommentary from the authors: Width of excision margins after breast conserving surgery for invasive breast cancer and distant recurrence and survival – The BMJ
News Release: Experts call for adequate tumour free margins in breast cancer surgery – BMJ Newsroom
Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations.
23 Sep, 2022 | 13:07h | UTC
Commentary on Twitter
Chimeric antigen receptor T cells have revolutionised the treatment of hematological malignancies.
What practical aspects of a patient’s journey through this treatment should clinicians know about and what are current best practices to manage toxicities?https://t.co/idlA2Lv9uR
— The BMJ (@bmj_latest) September 4, 2022
The current state of the art and future trends in RAS-targeted cancer therapies.
22 Sep, 2022 | 13:01h | UTC
Commentary on Twitter
New reading for the weekend: 'The current state of the art and future trends in RAS-targeted cancer therapies' by @salmanpunekar, @DrBenNeel, @VamsiVelcheti & Kwok-Kin Wong https://t.co/BfDYYrGqb7 #lcsm #PancSM #crcsm #caxtx#medonc pic.twitter.com/OZNoMYAjTV
— NatureRevClinOncol (@NatRevClinOncol) August 26, 2022
ASCO Guideline | Integrative medicine for pain management in oncology.
21 Sep, 2022 | 13:22h | UTC
Single-arm Phase 1b/2 study | Enfortumab Vedotin plus Pembrolizumab in previously untreated advanced urothelial cancer.
21 Sep, 2022 | 13:10h | UTC
M-A of randomized trials | Prophylactic central neck lymph node dissection in low-risk thyroid carcinoma patients does not decrease the incidence of locoregional recurrence.
21 Sep, 2022 | 13:07h | UTCProphylactic Central Neck Lymph Node Dissection in Low-risk Thyroid Carcinoma Patients Does Not Decrease the Incidence of Locoregional Recurrence: A Meta-analysis of Randomized Trials – Annals of Surgery (link to abstract – $ for full-text)
Preliminary results of a RCT | Once-only colonoscopy vs. two rounds of fecal immunochemical testing 2 years apart for colorectal cancer screening.
20 Sep, 2022 | 13:29h | UTCOnce-only colonoscopy or two rounds of faecal immunochemical testing 2 years apart for colorectal cancer screening (SCREESCO): preliminary report of a randomised controlled trial – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)
Commentary: Two Rounds of FIT vs Single Colonoscopy as a One-time CRC Screening – Medscape (free registration required)
M-A of randomized trials | Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer.
20 Sep, 2022 | 13:23h | UTCRelated:
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer – New England Journal of Medicine
Single-arm phase 1/2 study | Tumor-agnostic efficacy and safety of Selpercatinib in patients with RET fusion-positive solid tumors other than lung or thyroid tumors.
20 Sep, 2022 | 13:18h | UTCInvited Commentary: Tissue-agnostic RET inhibition: can you trust your target? – The Lancet Oncology
Commentary from the author on Twitter (thread – click for more)
🥁🚨Hot off the press in Lancet Oncology 👉So honored to share A MAJOR milestone in #PrecisionMedicine
👉Tumour-agnostic efficacy + safety of Selpercatinib in RET fusion-positive solid tumours -LIBRETTO-001 @TheLancetOncol @myESMO #ESMO22 @MDAndersonNews https://t.co/xriueGKju0 pic.twitter.com/e0fkih6Aov— Vivek Subbiah, MD (@VivekSubbiah) September 12, 2022
Systematic Review | Debulking hysterectomy followed by chemoradiotherapy vs. chemoradiotherapy alone for women with locally advanced cancer of the cervix – not enough evidence to guide recommendations.
19 Sep, 2022 | 12:39h | UTC
RCT | Intensity-modulated radiotherapy vs. stereotactic body radiotherapy for prostate cancer.
19 Sep, 2022 | 12:31h | UTCIntensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary from the author on Twitter (thread – click for more)
My first Tweetorial 🧵 2 year toxicity results of PACE B published here. Big thanks to the 🇬🇧🇨🇦 and🇮🇪collaborators and the 874 men with prostate cancer who made this trial possible https://t.co/mERz2ox8TM
— Alison Tree 💙 (@alison_tree) September 14, 2022
Phase 2 RCT | Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma.
19 Sep, 2022 | 12:32h | UTCCombined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial – The Lancet (free registration required for full-text)
ASCO Rapid Recommendation | Systemic therapy update on 177Lutetium-PSMA-617 for metastatic castration-resistant prostate cancer.
19 Sep, 2022 | 12:31h | UTC
RCT | Short-term outcomes of laparoscopy-assisted vs. open surgery for patients with low rectal cancer.
16 Sep, 2022 | 12:58h | UTC
Commentary on Twitter
https://twitter.com/JAMAOnc/status/1570532915393744896
Cohort Study | Long-term outcomes among men undergoing active surveillance for prostate cancer.
15 Sep, 2022 | 13:11h | UTCInvited Commentary: Exploring the Long-term Outcomes of Active Surveillance Among Men With Prostate Cancer—Best for Whom? – JAMA Network Open
RCT | Robotic vs. laparoscopic surgery for middle and low rectal cancer.
15 Sep, 2022 | 13:09h | UTCRobotic versus laparoscopic surgery for middle and low rectal cancer (REAL): short-term outcomes of a multicentre randomised controlled trial – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)
Commentaries:
Robotic Surgery Tops Laparoscopic Surgery for Middle and Low Rectal Cancer — Randomized trial shows fewer positive circumferential resection margins with robotic technique – MedPage Today (free registration required)
Commentaries on Twitter
RCT: Robot versus laparoscopic surgery for middle and low rectal cancer – 11 hospitals, 1171 patients
🤖 vs lap:
CRM+ 4% vs 7%
Complications 16% vs 23%
APR 17% vs 23%
Conversion 2% vs 4%https://t.co/3mU9m7sDVB#colorectalcancer #colorectalsurgery— Ville Sallinen (@villesallinen) September 8, 2022
New research online – Feng et al – Robotic versus laparoscopic surgery for middle and low rectal cancer (REAL): short-term outcomes of a multicentre randomised controlled trialhttps://t.co/B60DV5e4iJ#GITwitter @OncoAlert #rectalcancer #crcsm #SoMe4Surgery pic.twitter.com/9NoXXyCGwM
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) September 8, 2022
RCT | Extended duration thromboprophylaxis (continued for 56 days postoperatively) is not beneficial after surgical resection of colorectal cancer.
14 Sep, 2022 | 13:22h | UTC
Phase 2 RCT | Sequencing of Ipilimumab plus Nivolumab and Encorafenib plus Binimetinib for untreated BRAF-mutated metastatic melanoma.
14 Sep, 2022 | 13:01h | UTCSequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Data from the phase II SECOMBIT trial of treatment sequencing for BRAF-mutant metastatic melanoma suggests that nivo+ipi followed by encorafenib + binimetinib results in better OS than the reverse sequence, although with a greater risk of grade 3-4 AEs: https://t.co/9jC2oMI4Az
— NatureRevClinOncol (@NatRevClinOncol) September 7, 2022
RCT | Efficacy and safety of carboplatin with nab-paclitaxel vs. docetaxel in older patients with squamous non-small-cell lung cancer.
14 Sep, 2022 | 13:00h | UTC
Commentary on Twitter
New research: in a ph3 RCT pts aged 70 yrs and older with squamous non-small-cell #lungcancer, overall survival was significantly longer with #carboplatin & nab-paclitaxel vs #docetaxel
👉https://t.co/qOuaVpO61f pic.twitter.com/TSnMguOkoR— The Lancet Healthy Longevity (@LancetLongevity) December 9, 2021
RCT | Dexamethasone is not effective for the treatment of dyspnea in patients with cancer and increases the risk of adverse events.
13 Sep, 2022 | 13:22h | UTCEffect of dexamethasone on dyspnoea in patients with cancer (ABCD): a parallel-group, double-blind, randomised, controlled trial – The Lancet Oncology (free for a limited period)
Commentary on Twitter
Our phase III randomized study, published in Lancet Oncology today, showed high-dose steroid didn’t improve SOB and should not be used routinely in pts with lung ca for SOB palliation. My personal link in Lancet Oncology article ⁰https://t.co/Mj0AAzMujB pic.twitter.com/FMG7csHZsn
— Joe Y Chang (@JoeChangMD) September 7, 2022
Phase 2 single-arm study | Neoadjuvant Cemiplimab for stage II to IV cutaneous squamous-cell carcinoma.
13 Sep, 2022 | 13:11h | UTCNeoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Neoadjuvant Cemiplimab Induces Promising Pathologic Complete Response in CSCC – Cancer Network
Commentary on Twitter
A phase 2, multicenter study showed that four doses of neoadjuvant cemiplimab (anti–PD-1 antibody) led to a pathological complete response in 51% of patients with locally advanced cutaneous squamous-cell carcinoma. #ESMO22 https://t.co/NbICkb5kLM pic.twitter.com/a67fgxKBLy
— NEJM (@NEJM) September 12, 2022
RCT | Five-year analysis of adjuvant Pembrolizumab or placebo in stage III melanoma.
13 Sep, 2022 | 13:03h | UTCFive-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma – NEJM Evidence
Systematic Review | Ultra‐radical (extensive) surgery vs. standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.
13 Sep, 2022 | 12:56h | UTCRelated Study: Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer – New England Journal of Medicine